Aclaris Therapeutics (ACRS) News Today $4.52 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.50 -0.02 (-0.38%) As of 05/22/2026 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Aclaris Therapeutics Maps Immunology Pipeline Catalysts at BofA Healthcare ConferenceMay 16, 2026 | americanbankingnews.comAclaris Therapeutics (NASDAQ:ACRS) Upgraded to "Hold" at Wall Street ZenMay 16, 2026 | americanbankingnews.comAclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 14, 2026 | seekingalpha.comAclaris Therapeutics to Participate in the 2026 Bank of America Healthcare ConferenceMay 8, 2026 | globenewswire.comAclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results, Beats Estimates By $0.01 EPSMay 7, 2026 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Sets New 12-Month High Following Earnings BeatMay 7, 2026 | marketbeat.comAclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateMay 7, 2026 | globenewswire.comAclaris Therapeutics (ACRS) to Release Earnings on ThursdayMay 7, 2026 | marketbeat.comGuggenheim initiates coverage of Aclaris Therapeutics (ACRS) with buy recommendationMay 6, 2026 | msn.comAclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by GuggenheimMay 6, 2026 | marketbeat.comCompanies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In GrowthMay 4, 2026 | finance.yahoo.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 3, 2026 | marketbeat.comAclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates TranscriptApril 28, 2026 | seekingalpha.comAclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates - SlideshowApril 28, 2026 | seekingalpha.comAclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen PlanusApril 28, 2026 | marketbeat.comAclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti ...April 28, 2026 | markets.businessinsider.comAclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 InhibitorApril 28, 2026 | globenewswire.comAclaris Therapeutics (NASDAQ:ACRS) Major Shareholder Sells $1,359,000.00 in StockApril 28, 2026 | insidertrades.comAclaris Therapeutics (NASDAQ:ACRS) Major Shareholder Braden Michael Leonard Sells 300,000 SharesApril 27, 2026 | marketbeat.comAclaris Therapeutics to Announce Phase 1a Trial Results for ATI-052 and Lead Indication Selection for ATI-2138 on April 28, 2026April 27, 2026 | quiverquant.comQAclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026April 27, 2026 | globenewswire.comAclaris Therapeutics, Inc. ($ACRS) CEO 2025 Pay RevealedApril 23, 2026 | quiverquant.comQOppenheimer initiates coverage of Aclaris Therapeutics (ACRS) with outperform recommendationApril 16, 2026 | msn.comAclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual ConferenceApril 8, 2026 | globenewswire.comAclaris Therapeutics Reports Positive Phase 2a Trial Results for ATI-2138 in Atopic Dermatitis, Showing Significant Improvements in Disease Severity and Quality of LifeMarch 27, 2026 | quiverquant.comQResults Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138March 27, 2026 | globenewswire.comAclaris to present phase 2a ATI-2138 data at dermatology meetingMarch 26, 2026 | msn.comAclaris completes enrollment in phase 2 trial of Bosakitug for atopic dermatitisMarch 25, 2026 | msn.comAclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual MeetingMarch 20, 2026 | globenewswire.comAclaris Therapeutics Completes Patient Enrollment in Phase 2 Trial for Bosakitug in Atopic Dermatitis, Top Line Results Expected Q4 2026March 18, 2026 | quiverquant.comQAclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic DermatitisMarch 18, 2026 | globenewswire.comAclaris Therapeutics Raises $20 Million in Equity FinancingMarch 11, 2026 | tipranks.comAclaris Therapeutics Raises Capital via Institutional Stock SaleMarch 10, 2026 | tipranks.comAclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | markets.businessinsider.comAclaris Therapeutics Reports Positive Interim Phase 1a Results for ATI-052 and Advances Pipeline with Upcoming Trials and IND ApplicationFebruary 26, 2026 | quiverquant.comQAclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateFebruary 26, 2026 | globenewswire.comAclaris Therapeutics, Inc.: Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052February 24, 2026 | finanznachrichten.deAclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052February 24, 2026 | globenewswire.comAclaris lines up February spotlight at major biotech investor conferencesFebruary 8, 2026 | msn.comAclaris Therapeutics to Participate in Two February Healthcare ConferencesFebruary 4, 2026 | markets.businessinsider.comExperimental hair-loss drug sparks rapid regrowth in severe alopecia studyFebruary 3, 2026 | msn.comAclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)January 27, 2026 | markets.businessinsider.comAclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)January 27, 2026 | globenewswire.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Moderate Buy" from AnalystsJanuary 23, 2026 | marketbeat.comAclaris pushes new antibody into skin disease trial, eyes asthma nextJanuary 20, 2026 | msn.comAclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052January 13, 2026 | finance.yahoo.comAclaris Therapeutics, Inc.: Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052January 12, 2026 | finanznachrichten.deAclaris Therapeutics Initiates Phase 1b Trial for ATI-052 in Atopic DermatitisJanuary 12, 2026 | quiverquant.comQAclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052January 12, 2026 | globenewswire.comEarly trial data puts Aclaris’ ATI-052 on fast track toward bigger betsJanuary 8, 2026 | msn.com Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACRS Media Mentions By Week ACRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼0.000.47▲Average Medical News Sentiment ACRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼03▲ACRS Articles Average Week Get the Latest News and Ratings for ACRS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aclaris Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Enliven Therapeutics News Today Nanobiotix News Today Ultragenyx Pharmaceutical News Today Relay Therapeutics News Today Immunome News Today Kodiak Sciences News Today Mineralys Therapeutics News Today Zai Lab News Today Tyra Biosciences News Today HUTCHMED News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
